As a result of its recently announced change in commercial strategy to close its wholly owned European subsidiaries and prioritize its activities in
Financial outlook
** Revenue is expected to, long term, exceed
** Gross margin is expected to, long term, exceed 60%.
This disclosure contains information that IRRAS is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on
For more information, please contact:
President and Chief Executive Officer
ir@irras.com
About IRRAS
IRRAS is a global medical care company focused on delivering innovative medical solutions to improve the lives of critically ill patients. IRRAS designs, develops, and commercializes neurocritical care products that transform patient outcomes and decrease the overall cost of care by addressing complications associated with current treatment methodologies. IRRAS markets and sells its comprehensive, innovative IRRAflow and Hummingbird ICP Monitoring product lines to hospitals worldwide through its direct sales organization in
IRRAS maintains its headquarters in
IRRAS is listed on Nasdaq Stockholm (ticker: IRRAS).
https://news.cision.com/irras/r/irras-announces-reassessment-of-financial-outlook,c3813370
https://mb.cision.com/Main/16550/3813370/2215012.pdf
(c) 2023 Cision. All rights reserved., source